TP53 and metastatic malignant neoplasm: This is not only because of the high frequency of adverse cytogenetic (e.g., -7/-7q, -5/-5q, -3/-3q, -17/-17p, complex and/or monosomal karyotypes) and molecular lesions (e.g., TP53 mutations), but also due to the sequelae of prior chemotherapy and sometimes persistent primary disease, particularly metastatic cancer or lymphoma.